Investor Presentaiton
Sharing data from our earlier stage oncology program
Lung
•
KEYNOTE-671:
•
.
Presented positive overall survival
data at ESMO from Phase 3 study
⚫ KEYTRUDA is the first and only
anti-PD(L)-1 therapy to
demonstrate statistically
significant improvement in OS
and EFS as perioperative
treatment for resectable stage II,
IIIA or IIIB NSCLC versus pre-
operative chemotherapy
•
OS benefit generally consistent
across majority of subgroups
6th KEYTRUDA indication for
NSCLC to receive FDA approval
Women's Cancers
•
Presented positive data at
ESMO:
⚫ KEYNOTE-756 in patients with
ER+ HER2-breast cancer
•
•
KEYNOTE-522 in patients with
high-risk early-stage TNBC
KEYNOTE-A18 in patients with
high-risk locally advanced cervical
cancer
.
FDA granted priority review with
target action date of January 20th
Bladder
•
KEYNOTE-123:
Announced Phase 3 trial
evaluating KEYTRUDA for the
adjuvant treatment of certain
patients with localized muscle-
invasive urothelial carcinoma and
locally advanced urothelial
carcinoma significantly improved
disease-free survival
MERCK 22View entire presentation